Business
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results
– ZYNRELEF® and APONVIE® Drive 65% Year-Over-Year Net Revenue Growth in Acute Care Franchise– Achieved $154.9 Million in 2025 Net Revenue– Issues Full-Year
About this update from Heron Therapeutics, Inc.
– ZYNRELEF® and APONVIE® Drive 65% Year-Over-Year Net Revenue Growth in Acute Care Franchise– Achieved $154.9 Million in 2025 Net Revenue– Issues Full-Year 2026 Net Revenue Guidance of $173 to $183 Million and Adjusted EBITDA of $10 to $20 Million CARY, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the three and twelve months ended December 31, 2025, and highlighted recent corporate updates. “As demonstrated in today’s release, we are entering 2026 with exceptional momentum. The fourth quarter delivered the strongest results in the history of Heron’s Acute Care franchise, underscoring the success of the strategic decisions we implemented to unlock the full potential of these assets,” said Craig Collard, Chief Executive Officer of Heron. “The milestones achieved in 2025, particularly for ZYNRELEF - including enhanced distributor‑partner incentives, the seamless completion of the Vial Access Needle transition, and CMS approval of a product‑specific J‑Code - are already accelerating adoption and strengthening our competitive position in a large and underpenetrated market.” “With a more powerful commercial engine, expanding demand signals, and improved reimbursement clarity, we believe Heron is well‑positioned for continued share gains and meaningful revenue expansion in 2026 and beyond.” Financial Guidance for 2026 Item2026 Full-Year Guidance for Net Revenue and Adjusted EBITDA (in millions)Net Revenue$173 to $183 millionAdjusted EBITDA$10 to $20 million Business Highlights – Heron’s Acute Care franchise delivered revenue growth of 57.3% year-over-year in Q4 2025 and 65.1% year-over-year for 2025 compared to 2024, reflecting continued commercial acceleration. – ZYNRELEF Updates: The permanent, product specific J-Code (J0668) for ZYNRELEF, granted by the Centers for Medicare and Medicaid Services (“CMS”), was approved effective October 1, 2025 – streamlining reimbursement and improving billing clarity across payer types and settings of care.Transition to the Vial Access Needle is complete, optimizing product preparation, handling, and operating field sterility with ZYNRELEF in hospitals and ambulatory surgical centers across the U.S.Through aligned partnerships with leading distributors, we are broadening account access...
View stock analysis, news, and events for Heron Therapeutics, Inc.